Solicitation of Nominations for Appointment to the Clinical Laboratory Improvement Advisory Committee (CLIAC), 53312-53313 [2021-20925]
Download as PDF
<![CDATA[
53312
Federal Register / Vol. 86, No. 184 / Monday, September 27, 2021 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Form number & name
57.306 Hemovigilance Module Annual Survey—Non-acute care facility ......
57.307 Hemovigilance Adverse Reaction—Acute Hemolytic Transfusion
Reaction .......................................................................................................
57.308 Hemovigilance Adverse Reaction—Allergic Transfusion Reaction ..
57.309 Hemovigilance Adverse Reaction—Delayed Hemolytic Transfusion
Reaction .......................................................................................................
57.310 Hemovigilance Adverse Reaction—Delayed Serologic Transfusion
Reaction .......................................................................................................
57.311 Hemovigilance Adverse Reaction—Febrile Non-hemolytic Transfusion Reaction ............................................................................................
57.312 Hemovigilance Adverse Reaction—Hypotensive Transfusion Reaction ................................................................................................................
57.313 Hemovigilance Adverse Reaction—Infection ....................................
57.314 Hemovigilance Adverse Reaction—Post Transfusion Purpura ........
57.315 Hemovigilance Adverse Reaction—Transfusion Associated Dyspnea ...............................................................................................................
57.316 Hemovigilance Adverse Reaction—Transfusion Associated Graft
vs. Host Disease ..........................................................................................
57.317 Hemovigilance Adverse Reaction—Transfusion Related Acute
Lung Injury ...................................................................................................
57.318 Hemovigilance Adverse Reaction—Transfusion Associated Circulatory Overload .........................................................................................
57.319 Hemovigilance Adverse Reaction—Unknown Transfusion Reaction
57.320 Hemovigilance Adverse Reaction—Other Transfusion Reaction .....
57.400 Outpatient Procedure Component—Annual Facility Survey .............
57.401 Outpatient Procedure Component—Monthly Reporting Plan ...........
57.402 Outpatient Procedure Component Same Day Outcome Measures
57.403 Outpatient Procedure Component—Monthly Denominators for
Same Day Outcome Measures ....................................................................
57.404 Outpatient Procedure Component—SSI Denominator .....................
57.405 Outpatient Procedure Component—Surgical Site (SSI) Event .........
57.500 Outpatient Dialysis Center Practices Survey ....................................
57.501 Dialysis Monthly Reporting Plan .......................................................
57.502 Dialysis Event ....................................................................................
57.503 Denominator for Outpatient Dialysis .................................................
57.504 Prevention Process Measures Monthly Monitoring for Dialysis .......
57.505 Dialysis Patient Influenza Vaccination ..............................................
57.506 Dialysis Patient Influenza Vaccination Denominator ........................
57.507 Home Dialysis Center Practices Survey ...........................................
Weekly Healthcare Personnel Influenza Vaccination Cumulative Summary
for Non-Long-Term Care Facilities ...............................................................
Weekly Healthcare Personnel Influenza Vaccination Cumulative Summary
for Long-Term Care Facilities ......................................................................
Weekly Resident Influenza Vaccination Cumulative Summary for Long-Term
Care Facilities ..............................................................................................
Annual Healthcare Personnel Influenza Vaccination Summary ......................
Total ..........................................................................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–20846 Filed 9–24–21; 8:45 am]
lotter on DSK11XQN23PROD with NOTICES1
BILLING CODE 4163–18–P
35/60
292
500
500
4
4
20/60
20/60
667
667
500
1
20/60
167
500
2
20/60
333
500
4
20/60
667
500
500
500
1
1
1
20/60
20/60
20/60
167
167
167
500
1
20/60
167
500
1
20/60
167
500
1
20/60
167
500
500
500
700
700
200
2
1
1
1
12
1
20/60
20/60
20/60
10/60
15/60
40/60
333
167
167
117
2,100
133
200
700
700
7,200
7,200
7,200
7,200
1,730
615
615
430
400
100
5
1
12
30
30
12
50
5
1
40/60
40/60
40/60
12/60
5/60
25/60
10/60
75/60
10/60
10/60
30/60
53,333
46,667
2,333
1,440
7,200
90,000
36000
25,950
5,125
513
215
125
52
60/60
6,500
1,200
52
60/60
62,400
2,500
5,000
52
1
60/60
120/60
130,000
10,000
........................
........................
........................
1,718,591
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Appointment to the Clinical Laboratory
Improvement Advisory Committee
(CLIAC)
Notice.
The Centers for Disease
Control and Prevention (CDC) is seeking
nominations for membership on the
CLIAC. The CLIAC consists of 20
experts including the Chair, represents
18:08 Sep 24, 2021
Jkt 253001
PO 00000
Frm 00051
Fmt 4703
Total burden
(hours)
1
SUMMARY:
VerDate Sep<11>2014
Avg. burden
per response
(hours)
500
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ACTION:
Number of
responses per
respondent
Sfmt 4703
a diverse membership across laboratory
specialties, professional roles
(laboratory management, technical
specialists, physicians, nurses) and
practice settings (academic, clinical,
public health), and includes a consumer
representative.
DATES: Nominations for membership on
CLIAC must be received no later than
March 1, 2022. Packages received after
this time will not be considered for the
current membership cycle.
ADDRESSES: All nominations should be
mailed to Nancy Anderson, MMSc,
MT(ASCP), CLIAC Secretary, Senior
Advisor for Clinical Laboratories,
Division of Laboratory Systems, Center
E:\FR\FM\27SEN1.SGM
27SEN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 184 / Monday, September 27, 2021 / Notices
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop V24–3,
Atlanta, Georgia 30329–4018,
Telephone: (404) 498–2741; or via email
at CLIAC@cdc.gov.
FOR FURTHER INFORMATION CONTACT:
Heather Stang, MS, Deputy Chief,
Quality and Safety Systems Branch,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop V24–3,
Atlanta, Georgia 30329–4018,
Telephone: (404) 498–2769; HStang@
cdc.gov.
SUPPLEMENTARY INFORMATION: The
Committee includes three ex officio
members (or designees), including the
Director, CDC; the Administrator,
Centers for Medicare & Medicaid
Services (CMS); and the Commissioner,
Food and Drug Administration (FDA). A
nonvoting representative from the
Advanced Medical Technology
Association (AdvaMed) serves as the
industry liaison. The Designated Federal
Official (DFO) or their designee and the
Executive Secretary are present at all
meetings to ensure meetings are within
applicable statutory, regulatory, and
HHS General Administration manual
directives.
Nominations are being sought for
individuals who have the expertise and
qualifications necessary to contribute to
the accomplishments of the committee’s
objectives. Nominees will be selected
based on expertise in the fields of
microbiology (including bacteriology,
mycobacteriology, mycology,
parasitology, and virology), immunology
(including histocompatibility),
chemistry, hematology, pathology
(including histopathology and cytology),
or genetic testing (including
cytogenetics); from representatives in
the fields of medical technology,
bioinformatics, public health, and
clinical practice; and from consumer
representatives. Federal employees will
not be considered for membership.
Members may be invited to serve for up
to four-year terms.
Selection of members is based on
candidates’ qualifications to contribute
to the accomplishment of CLIAC
objectives (https://www.cdc.gov/cliac/).
The U.S. Department of Health and
Human Services policy stipulates that
committee membership be balanced in
terms of points of view represented, and
the committee’s function. Appointments
shall be made without discrimination
VerDate Sep<11>2014
18:08 Sep 24, 2021
Jkt 253001
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens,
and cannot be full-time employees of
the U.S. Government. Current
participation on federal workgroups or
prior experience serving on a federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
advisory committees and multiple
committee memberships. Committee
members are Special Government
Employees (SGEs), requiring the filing
of financial disclosure reports at the
beginning and annually during their
terms. CDC reviews potential candidates
for CLIAC membership each year and
provides a slate of nominees for
consideration to the Secretary of HHS
for final selection. HHS notifies selected
candidates of their appointment near
the start of the term in July, or as soon
as the HHS selection process is
completed. Note that the need for
different expertise varies from year to
year and a candidate who is not selected
in one year may be reconsidered in a
subsequent year. Candidates should
submit the following items:
D Current curriculum vitae, including
complete contact information
(telephone numbers, mailing address,
email address).
D At least one letter of
recommendation from person(s) not
employed by the U.S. Department of
Health and Human Services.
(Candidates may submit letter(s) from
current HHS employees if they wish,
but at least one letter must be submitted
by a person not employed by an HHS
agency (e.g., CDC, NIH, FDA, etc.).
Nominations may be submitted by the
candidate, or by the person/organization
recommending the candidate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–20925 Filed 9–24–21; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
53313
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–21–21IE; Docket No. CDC–2021–
0103]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled Understanding Health System
Approaches to Chronic Pain
Management. The proposed study is
designed to evaluate the effects of
evidence-based guidelines related to
chronic pain management and opioid
prescribing.
SUMMARY:
CDC must receive written
comments on or before November 26,
2021.
DATES:
You may submit comments,
identified by Docket No. CDC–2021–
0103 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
ADDRESSES:
Please note: Submit all comments through
the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\27SEN1.SGM
27SEN1
]]>Agencies
[Federal Register Volume 86, Number 184 (Monday, September 27, 2021)]
[Notices]
[Pages 53312-53313]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-20925]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Solicitation of Nominations for Appointment to the Clinical
Laboratory Improvement Advisory Committee (CLIAC)
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC) is
seeking nominations for membership on the CLIAC. The CLIAC consists of
20 experts including the Chair, represents a diverse membership across
laboratory specialties, professional roles (laboratory management,
technical specialists, physicians, nurses) and practice settings
(academic, clinical, public health), and includes a consumer
representative.
DATES: Nominations for membership on CLIAC must be received no later
than March 1, 2022. Packages received after this time will not be
considered for the current membership cycle.
ADDRESSES: All nominations should be mailed to Nancy Anderson, MMSc,
MT(ASCP), CLIAC Secretary, Senior Advisor for Clinical Laboratories,
Division of Laboratory Systems, Center
[[Page 53313]]
for Surveillance, Epidemiology and Laboratory Services, Office of
Public Health Scientific Services, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, Georgia
30329-4018, Telephone: (404) 498-2741; or via email at [email protected].
FOR FURTHER INFORMATION CONTACT: Heather Stang, MS, Deputy Chief,
Quality and Safety Systems Branch, Division of Laboratory Systems,
Center for Surveillance, Epidemiology and Laboratory Services, Office
of Public Health Scientific Services, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, Georgia
30329-4018, Telephone: (404) 498-2769; [email protected].
SUPPLEMENTARY INFORMATION: The Committee includes three ex officio
members (or designees), including the Director, CDC; the Administrator,
Centers for Medicare & Medicaid Services (CMS); and the Commissioner,
Food and Drug Administration (FDA). A nonvoting representative from the
Advanced Medical Technology Association (AdvaMed) serves as the
industry liaison. The Designated Federal Official (DFO) or their
designee and the Executive Secretary are present at all meetings to
ensure meetings are within applicable statutory, regulatory, and HHS
General Administration manual directives.
Nominations are being sought for individuals who have the expertise
and qualifications necessary to contribute to the accomplishments of
the committee's objectives. Nominees will be selected based on
expertise in the fields of microbiology (including bacteriology,
mycobacteriology, mycology, parasitology, and virology), immunology
(including histocompatibility), chemistry, hematology, pathology
(including histopathology and cytology), or genetic testing (including
cytogenetics); from representatives in the fields of medical
technology, bioinformatics, public health, and clinical practice; and
from consumer representatives. Federal employees will not be considered
for membership. Members may be invited to serve for up to four-year
terms.
Selection of members is based on candidates' qualifications to
contribute to the accomplishment of CLIAC objectives (https://www.cdc.gov/cliac/).
The U.S. Department of Health and Human Services policy stipulates
that committee membership be balanced in terms of points of view
represented, and the committee's function. Appointments shall be made
without discrimination on the basis of age, race, ethnicity, gender,
sexual orientation, gender identity, HIV status, disability, and
cultural, religious, or socioeconomic status. Nominees must be U.S.
citizens, and cannot be full-time employees of the U.S. Government.
Current participation on federal workgroups or prior experience serving
on a federal advisory committee does not disqualify a candidate;
however, HHS policy is to avoid excessive individual service on
advisory committees and multiple committee memberships. Committee
members are Special Government Employees (SGEs), requiring the filing
of financial disclosure reports at the beginning and annually during
their terms. CDC reviews potential candidates for CLIAC membership each
year and provides a slate of nominees for consideration to the
Secretary of HHS for final selection. HHS notifies selected candidates
of their appointment near the start of the term in July, or as soon as
the HHS selection process is completed. Note that the need for
different expertise varies from year to year and a candidate who is not
selected in one year may be reconsidered in a subsequent year.
Candidates should submit the following items:
[ssquf] Current curriculum vitae, including complete contact
information (telephone numbers, mailing address, email address).
[ssquf] At least one letter of recommendation from person(s) not
employed by the U.S. Department of Health and Human Services.
(Candidates may submit letter(s) from current HHS employees if they
wish, but at least one letter must be submitted by a person not
employed by an HHS agency (e.g., CDC, NIH, FDA, etc.).
Nominations may be submitted by the candidate, or by the person/
organization recommending the candidate.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-20925 Filed 9-24-21; 8:45 am]
BILLING CODE 4163-18-P
